VRNA Dec 2024 12.500 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:38PM EDT. Market open.
| Previous close | 2.6500 |
| Open | 1.8200 |
| Bid | 1.4000 |
| Ask | 1.9000 |
| Strike | 12.50 |
| Expiry date | 2024-12-20 |
| Day's range | 1.8200 - 1.8200 |
| Contract range | N/A |
| Volume | |
| Open interest | 87 |
GlobeNewswireVerona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treat
Investor's Business DailyWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
- GuruFocus.com
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview
Insights into Verona Pharma's First Quarter Performance and Future Prospects
© 2024 Yahoo. All rights reserved.